Free Trial Information
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...November to complete a Phase III trial of bomedemstat (IMG-7289), a small molecule inhibitor of LSD1...
Read More
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...used to complete a Phase III trial of bomedemstat (IMG-7289), a small molecule inhibitor of LSD1...
...raised $1.1 billion in April. TARGETSER (ESR1) - Estrogen receptor 1ESR2 - Estrogen receptor 2LSD1 (KDM1A) – Lysine-specific demethylase 1 BC...
Read More
BioCentury | Nov 21, 2019

Entinostat-derived LSD1 and HDAC dual inhibitor for pediatric glioma

...DISEASE CATEGORY: Cancer INDICATION: Brain cancer An HDAC and LSD1 inhibitor could treat diffuse intrinsic pontine...
...treat diffuse intrinsic pontine glioma, a subtype of pediatric brain cancer. A dual HDAC and LSD1...
...HDAC3, in Phase II for gastrointestinal tumors and Phase I/II for melanoma. TARGET/MARKER/PATHWAY: Lysine-specific demethylase 1 (LSD1; KDM1A...
Read More
BioCentury | Sep 19, 2019
Tools & Techniques

Atomwise's JV spree

Drug developers signing up to partner with Atomwise for hit discovery and lead optimization said deal structures made it attractive to take the plunge on the AI company's emerging technology. Last week, Atomwise Inc. announced...
Read More
BioCentury | Jun 20, 2019
Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

...complex 1 (mTORC1) Cancer Preclinical K-Ras (KRAS) G12C mutation Cancer Preclinical Beactica AB Lysine-specific demethylase 1 (LSD1; KDM1A...
Read More
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
Read More
BioCentury | Mar 21, 2019
Financial News

Imago to deploy $40M series B for Phase II trials

...year in AML, polycythemia vera and essential thrombocythemia. IMG-7289 is a small molecule lysine-specific demethylase 1 (LSD1; KDM1A...
...Clarus Ventures. Omega Funds' Dina Chaya will join Imago's board. Sandi Wong, Staff Writer IMG-7289 Imago BioSciences Inc. Omega Funds Lysine-specific demethylase 1 (LSD1) (KDM1A) Myeloproliferative...
Read More
BioCentury | Dec 6, 2018
Translation in Brief

Opening chromatin: long-term detriment?

...euchromatic histone-lysine N-methyltransferase 2 (EHMT2; G9A), enhancer of zeste homolog 2 (EZH2) and lysine-specific demethylase 1 (LSD1; KDM1A...
...EZH2 inhibitor, tazemetostat (E7438; EPZ-6438), in Phase II testing. At least six other companies have LSD1...
Read More
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...cancer metabolism and epigenetics. Other epigenetic synthetic lethal interactions include inhibition of the histone demethylase LSD1...
...from Beta Cat Pharmaceuticals Inc. ( No. 177 ). An undisclosed degrader targeting lysine demethylase LSD1...
...receptor-associated kinase 4 KMO - Kynurenine-3-monoxygenase LMO2 - LIM domain only 2 LSD1 (KDM1A) - Lysine-specific demethylase 1...
Read More
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

...the transcriptional repressors GFI1 and GFI1B. Preclinical studies have shown inhibitors of the epigenetic enzyme LSD1...
...effects in acute myelogenous leukemia (AML). At least eight companies are developing cancer therapies targeting LSD1...
...independent 1B transcription repressor GPC2 - Glypican 2 GPNMB - Glycoprotein NMB LSD1 (KDM1A) - Lysine-specific demethylase 1...
Read More
Items per page:
1 - 10 of 95